Given that predictable hematological toxicity has prevented adequate dose-escalation and the encouraging clinical efficacy demonstrated in AML, the addition of G-CSF to enable dose-escalation and full evaluation in ovarian cancer should be considered in case of further development. This evidence concerns the gene CSF3 and ovarian carcinoma.